Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | HPN328, a tri-specific T-cell engager, in SCLC and neuroendocrine cancers

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, describes the interim results of an ongoing phase I/IIa study (NCT04471727) of HPN328, a tri-specific, DLL3-targeting T-cell engager, in patients with small cell lung cancer (SCLC) and other neuroendocrine cancers. The investigational therapy binds to T-cells and stimulates their activity. Three doses were assessed and partial responses were reported in a number of patients. HPN328 additionally was well tolerated, with cases of cytokine release syndrome being manageable. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL

Transcript (edited for clarity)

Tomorrow I’ll present a poster on this tri-specific T-cell engager made by Harpoon. It’s a DLL3 specific, tri-specific that also binds to T-cells, stimulates the T-cells and introduces them into the tumor.

So we’ve treated about three different dose levels. We have had a couple partial responses and some other patients with target lesion shrinkage, and so the dose escalation continues...

Tomorrow I’ll present a poster on this tri-specific T-cell engager made by Harpoon. It’s a DLL3 specific, tri-specific that also binds to T-cells, stimulates the T-cells and introduces them into the tumor.

So we’ve treated about three different dose levels. We have had a couple partial responses and some other patients with target lesion shrinkage, and so the dose escalation continues. It’s been well tolerated with manageable cytokine release.

Read more...